|1.||Shaw, Chen-Fu: 2 articles (04/2005 - 01/2005)|
|2.||Chien, Chiang-Ting: 2 articles (04/2005 - 01/2005)|
|3.||Li, Ping-Chia: 2 articles (04/2005 - 01/2005)|
|4.||Advenier, C: 2 articles (09/2004 - 11/2000)|
|5.||Linardi, Alessandra: 1 article (01/2016)|
|6.||Hyslop, Stephen: 1 article (01/2016)|
|7.||Rocha-E-Silva, Thomaz A A: 1 article (01/2016)|
|8.||Antunes, Edson: 1 article (01/2016)|
|9.||Griebel, Guy: 1 article (05/2011)|
|10.||Cohen, Caroline: 1 article (05/2011)|
|1.||Major Depressive Disorder (Major Depressive Disorders)
|2.||Anxiety Disorders (Anxiety Disorder)
03/17/2008 - "Visceral pain responses during colorectal distension were attenuated by both compounds, but aprepitant (19+/-6% inhibition, P<0.01) was slightly more effective than saredutant (10+/-9% inhibition, P<0.05). "
01/01/1997 - "RP-67580 abolished CGRP-induced gastric emptying inhibition, whereas SR-48968 only diminished visceral pain. "
06/15/2006 - "Tachykinins control gastrointestinal motility and modulate somatic and visceral pain sensation; therefore, the effect of tachykinin receptor antagonists in a rat model of PI using NK(1-3) antagonists, SR140333, SR48968, and SR142801, was investigated. "
08/01/1997 - "With the exception of the response of SR 48968, which was equipotent in both models of nociception, FK 888, GR 82334 and SR 142801 were about 2-25-fold less potent at the ID50 level against the capsaicin-induced pain. "
01/01/2000 - "Our results show that (i) the modified formalin test elicited an intense grooming behaviour and expression of c-Fos in numerous forebrain and brainstem areas, (ii) both tachykinin receptor antagonists were able to attenuate the behavioural response to pain and to reduce the formalin-induced c-Fos expression in some, but not all, brain areas, and (iii) the neurokinin-1 antagonist, RP 67580, was more effective in inhibiting the behavioural response to formalin and the pain-induced activation of c-Fos than the antagonist for neurokinin-2 receptors, SR 48968, indicating that neurokinin-1 receptors are preferentially activated in neurokinin-containing pathways responding to noxious stimuli. "
|5.||Asthma (Bronchial Asthma)
02/01/2001 - "Further studies are needed to assess the value of SR 48968C and other NK receptor antagonists in the treatment of asthma"
06/01/1999 - "1. In a guinea-pig model of allergic asthma, we investigated the involvement of the tachykinin NK2 receptors in allergen-induced early (EAR) and late (LAR) asthmatic reactions, airway hyperreactivity (AHR) after these reactions and inflammatory cell influx in the airways, using the selective non-peptide NK2 receptor antagonist SR48968. "
01/01/2004 - "Clinical trials in humans assessing the utility of tachykinin receptor antagonists such as nepadutant and saredutant for the treatment of asthma are limited, and the results for the most part have been inconclusive. "
02/01/2001 - "SR 48968C had no significant effect on PC20AMP or on FEV1 measured on day 1 and 9, and morning and evening peakflow measured at home on day 2-8. Thus, although SR 48968C was administrated in a dosage that might cause a demonstrable blocking effect on airway NK-2 receptors in asthma, it did not have a significant bronchodilatory or bronchoprotective effect against adenosine hyperresponsiveness in this study. "
06/01/1999 - "Using a guinea pig model of allergic asthma, we investigated the effects of the inhaled, highly selective nonpeptide tachykinin NK1 and NK2 receptor antagonists SR 140333 and SR 48968, respectively, on allergen-induced early (EAR) and late (LAR) asthmatic reactions, airway hyperreactivity (AHR) after these reactions, and infiltration of inflammatory cells in the airways. "
|1.||SR 48968 (saredutant)
|2.||Neurokinin-2 Receptors (Neurokinin 2 Receptor)
|3.||Tachykinin Receptors (Tachykinin Receptor)
|5.||Neurokinin-1 Receptors (Neurokinin 1 Receptor)
|8.||MEN 11420 (Nepadutant)
|1.||Vagus Nerve Stimulation